The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who ...

The Trump administration's FDA and CDC is advising U.S. patients using the drug Ixchiq to hold off while U.S. health ...

The FDA and CDC recommended a pause in administering Ixchiq, a chikungunya vaccine, in adults ages 60 and above after 17 serious adverse events, including two deaths.  About 80,000 Ixchiq doses have ...

Hold off on inoculating people ages 60 and older against chikungunya infection with the Ixchiq vaccine, the FDA and CDC ...

The FDA and CDC are investigating reports of serious adverse events, including deaths, in recipients of Ixchiq.

The FDA and CDC have also recommended pausing the use of Ixchiq in seniors 60 years and older while safety investigations are ...

The CDC began recommending Ixchiq last year for adults traveling to countries where chikungunya is common. The vaccine uses a ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

U.S. health officials are telling travelers aged 60 and older to avoid a chikungunya vaccine while they investigate possible ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...